Durvalumab (Imfinzi) and Tremelimumab (Imjudo)

Canada’s Drug Agency (CDA-AMC) recommends that Imfinzi in combination with Imjudo and platinum-based chemotherapy should be reimbursed by public drug plans for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK genomic tumour aberrations if certain conditions are met. Imfinzi and Imjudo, in combination with platinum-based chemotherapy should only be covered to treat adult patients with NSCLC who have stage IV NSCLC with tumours that lack sensitizing EGFR mutations or ALK genomic tumour aberrations and have not previously been treated with chemotherapy or other systemic therapy for metastatic disease. Patients must not have untreated or progressive brain metastases. Imfinzi and Imjudo, in combination with platinum-based chemotherapy should only be reimbursed if prescribed by a clinician with expertise and experience in treating NSCLC, and if the cost of Imfinzi and Imjudo, in combination with platinum-based chemotherapy does not exceed the total cost of treatment with the least costly immune checkpoint inhibitors (ICIs) plus a platinum-based chemotherapy regimen reimbursed for the same indication.